← Back to all signals
RESEARCH PAPER ANALYSIS

Dopamine D2 Receptor Isoform Heteroreceptor Complexes with the Growth Hormone Secretagogue Receptor 1a Reveals Isoform-Specific Interaction Interface Dynamics.

Computational modeling and coarse-grained molecular dynamics show distinct structural dynamics and isoform-specific interaction interfaces for D2R short vs long isoforms in heteromers with GHSR1a, predicting differential effects on ligand binding and allosteric regulation.

PMID41902748
JournalJournal of chemical information and modeling
Publication Date2026-04-13
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Computational modeling and coarse-grained molecular dynamics show distinct structural dynamics and isoform-specific interaction interfaces for D2R short vs long isoforms in heteromers with GHSR1a, predicting differential effects on ligand binding and allosteric regulation.

WHY IT MATTERS

Research significance

By identifying isoform-dependent interfaces and predicted allosteric modulation within D2R/GHSR1a heteromers, the study provides a mechanistic framework that could be exploited to design heteromer- or isoform-selective therapeutics for Parkinson's disease, though experimental validation is required.

ABSTRACT

Source abstract

The dopamine D2 receptor (D2R), a class A G-protein-coupled receptor expressed in two isoforms at the central nervous system, has been implicated in several neuropsychiatric and neurodegenerative disorders. Although conventionally understood as a monomer, D2R can exist as homo- and heteroreceptor complexes, with each structural state conferring distinct functional properties. The heteromer formed by the D2R and the growth hormone secretagogue receptor (GHSR1a) has been primarily studied in the context of eating disorders, but more recently, in Parkinson's disease mouse models. Besides the neuropharmacological relevance of this heteromer, the molecular mechanisms underlying their interaction interface in complex formation have not been fully understood. Moreover, the specific contribution of each D2R isoform to both the formation and functional properties of the D2R/GHSR1a heteroreceptor complex remains to be elucidated. Therefore, in this study, we aimed to characterize the structural and dynamic differences between D2R short and long isoforms, both as monomers and within the D2R/GHSR1a heterocomplexes. Through computational methodologies including homology modeling, receptor-receptor docking, and coarse-grained molecular dynamic simulations, we observed distinct behaviors for D2R isoforms as monomers and in heteromeric assemblies with GHSR1a. Our findings showed differences in D2R isoform motions that may impact their activation along with isoform-specific interaction interfaces with GHSR1a. Furthermore, these differential interfaces promoted site-to-site and ligand-binding pocket differences for both D2R isoforms, suggesting isoform-specific allosteric regulation potentially mediated by GHSR1a within the D2R/GHSR1a heterocomplexes. Overall, our results highlight the isoform-dependent mechanisms within the D2R/GHSR1a heteromer that influence complex formation, ligand binding, and intracellular signaling, providing a framework for future therapeutic strategies targeting D2R/GHSR1a heteroreceptor complexes.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic